


A. Rosowsky
U.S.S.N.: 09/890,112
Page 2

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Previously Presented) A compound of the following Formula I:



wherein Ar is an optionally substituted heteroaromatic group having at least one amino substituent;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen;

Z represents optionally substituted ethylene or optionally substituted vinyl;


each R¹ and R² independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

A. Rosowsky
U.S.S.N.: 09/890,112
Page 3

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

2. (Cancelled).

3. (Previously Presented) A compound of the following Formula II:



wherein Ar is an optionally substituted heteroaromatic group having at least one amino substituent;

Z represents optionally substituted ethylene, or optionally substituted vinyl;


X is nitrogen;

each R¹ and R² independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

A. Rosowsky
U.S.S.N.: 09/890,112
Page 4

4. (Previously Presented) A compound of the following Formula IIA:



wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

Z represents optionally substituted ethylene or optionally substituted vinyl;


X is nitrogen;

each R¹ and R² independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

A. Rosowsky
 U.S.S.N.: 09/890,112
 Page 5

5. (Currently Amended) A compound of the following Formula III:



T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen wherein at least one of T, U, or V is optionally substituted nitrogen;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen;


Z represents optionally substituted ethylene or optionally substituted vinyl;

each R^1 , R^2 and R^3 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic, wherein at least one occurrence of R^3 is an amino group;

m and n are each independently an integer of from 0 to 4; o is an integer of from 1 to 5 and pharmaceutically acceptable salts thereof.

6. (Previously Presented) A compound of the following Formula IV:

A. Rosowsky
 U.S.S.N.: 09/890,112
 Page 6



U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen;


Z represents optionally substituted ethylene or optionally substituted vinyl;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

7. (Previously Presented) A compound of the following Formula IVA:

A. Rosowsky
 U.S.S.N.: 09/890,112
 Page 7



U and V are each independently optionally substituted carbon, or optionally substituted nitrogen; or

V is O or S;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen;

Z represents optionally substituted ethylene or optionally substituted vinyl;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

8. (Previously Presented) A compound of any one of claims 1, 3, 4, 5, 6 or 7 wherein Z is $-\text{CH}_2\text{CH}_2-$.

A. Rosowsky
U.S.S.N.: 09/890,112
Page 8

9. (Original) A compound of any one of claims 1, 2, 5, 6 or 7 wherein W is a bond, CH₂, CH₂CH₂, or NH.

10. (Previously Presented) A compound of claim 1 selected from the group consisting of:

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminoquinazolin-6-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminopyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;

and

pharmaceutically acceptable salts thereof.

11. (Currently Amended) A method of treating a patient suffering from or susceptible to a parasitic disease, comprising administering to the patient an effective amount of a compound of claim 1 or claim 10, wherein the patient's immune system is suppressed.

12. (Currently Amended) A method of treating a patient suffering from or susceptible to toxoplasmosis, comprising administering to the patient an effective amount of a compound of claim 1 or claim 10, wherein the patient's immune system is suppressed.

A. Rosowsky
U.S.S.N.: 09/890,112
Page 9

13. (Cancelled).
14. (Previously Presented) The method of claim 11 wherein the patient has a retrovirus infection.
15. (Previously Presented) The method of claim 11 wherein the patient has an HIV infection.
16. (Previously Presented) The method of claim 11 wherein the patient is suffering from AIDS.
17. (Previously Presented) The method of claim 11 wherein the patient has received or is receiving immunosuppressive cancer chemotherapy treatment.
18. (Currently Amended) A method of treating a patient suffering from ~~or-susceptible~~ to cryptosporidiosis, leishmaniasis or malaria, comprising administering to the patient an effective amount of a compound of claim 1 or claim 10, wherein the patient's immune system is suppressed.
19. (Currently Amended) A method of treating a patient suffering from ~~or-susceptible~~ to an infection of *Toxoplasma gondii*, *Pneumocystis carinii*, *Cryptosporidium*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malariae*, or *P. ovale*, comprising administering to the patient an effective amount of a compound of claim 1 or claim 10, wherein the patient's immune system is suppressed.
20. (Currently Amended) A method of treating a patient suffering from ~~or-susceptible~~ to a *Toxoplasma gondii* infection, comprising administering to the patient an effective amount of a compound of claim 1 or claim 10, wherein the patient's immune system is suppressed.

A. Rosowsky
U.S.S.N.: 09/890,112
Page 10

21. (Currently Amended) A method of treating a patient suffering from ~~or susceptible~~ to tuberculosis, comprising administering to the patient an effective amount of a compound of claim 1 or claim 10, wherein the patient's immune system is suppressed.

22. (Previously Presented) A method of claim 11 wherein the disease is treated without administration of a sulfa drug to the patient.

23. (Previously Presented) The method of claim 11 wherein the patient is a mammal.

24. (Previously Presented) The method of claim 11 wherein the patient is a human.

25. (Previously Presented) A method of claim 11 wherein the patient is a livestock animal, poultry or a domesticated animal.

26. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1-7 or 10.

27. (Cancelled).

28. (Previously Presented) The method of claim 12 wherein the patient has a retrovirus infection.

29. (Previously Presented) The method of claim 12 wherein the patient has an HIV infection.

A. Rosowsky
U.S.S.N.: 09/890,112
Page 11

30. (Previously Presented) The method of claim 12 wherein the patient is suffering from AIDS.
31. (Previously Presented) The method of claim 12 wherein the patient is a human.
32. (Previously Presented) The method of claim 20 wherein the patient is a human.
33. (Previously Presented) The method of claim 12 wherein the patient is a livestock animal, poultry or a domesticated animal.
34. (Previously Presented) The method of claim 20 wherein the patient is a livestock animal, poultry or a domesticated animal.